Biotech | August 08, 2021
TAKE divests stake in Navitas Life Sciences to HIG
The transaction is expected to close in the Q4FY22
The transaction is expected to close in the Q4FY22
This robust growth has come despite the raging pandemic for most part of the quarter
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
It is part of the company’s pain/analgesics portfolio of OTC products
Startup receives US $ 5 million in first round of funding
Subscribe To Our Newsletter & Stay Updated
